Accordingly, administration of recombinant PGRN or the PGRN-derived atsttrin in OA and RA animal models protected against the development of such rheumatic disorders by, at least in part, inhibiting the TNF-α/TNFR signaling in vivo [183,185,196,202,203,204]. Here, TNF is linked to rheumatoid arthritis.